ScienceDex / Researcher record
Moen, Robert Charles
- Inomagen Therapeutics, Inc (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #4,669
- Early Career
NIH Funding · FY2023
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
Linked awards ($M)Award-linked rank
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2021 | $462,689 | 1 | #23,186 |
| 2022 | $1,636,504 | 1 | #4,918 |
| 2023 | $1,749,913 | 1 | #4,669 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20211 record
- FY20221 record
- FY2023 · selected1 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2021 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2023 award records by amount
NIH award records listing Moen, Robert Charles as a PI. Multi-PI records show the full award amount for context.
- 5R44HL154912-03R44Contact PIA New and Disruptive Gene Based Therapy for Atrial Fibrillation$1.7Maward amount
Award organization
Organizations that administered FY2023 awards listing Moen, Robert Charles as a PI.
FY2023 award administered by Inomagen Therapeutics, Inc (IL).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2021First NIH AwardInomagen Therapeutics, Inc
- 2022$500K Cumulative Funding
- 2022$1M Cumulative Funding
- 2022$2M Cumulative Funding
- 2022Entered Top 50% NationallyRanked #4918
- 2022Entered Top 25% NationallyRanked #4918